Lilly Ventures Fund I LLC
CIK 1575852 · last filed 2018-04-23
Lilly Ventures Fund I LLC is a corporate insider who has filed 6 SEC Form 4 insider transactions across 6 companies since 2013. The most recent filing, for SURF, was dated Apr 23, 2018. Across all open-market trades the lifetime net is +$65.4M, making them a net buyer over the disclosed history. Current disclosed insider exposure totals $297.7M across reported positions. The firm reports its address in Indianapolis, IN. 9 SEC filings were submitted jointly with S. Edward Torres.
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Charts
Trading activity, where the exposure sits, and each trade against the stock price.
PTGX price and trades
Daily close with each Form 4 filing on this company marked: green = open-market buy, red = open-market sale, purple = grants, exercises, gifts and other non-market transactions. Marker size scales with the dollar value.
Shares held
Shares owned after each reported transaction on this company (direct holdings as reported).
Open-market buying and selling
by monthDollar value of open-market purchases (code P, up) and sales (code S, down) across all companies, by filing month. Grants, exercises and gifts are excluded.
Exposure by company
latestMost recently reported shares × current price. Faded bars (*) have had no filing in 3 years, so the person may no longer hold them. Click a bar to chart that company.
Filer Profile
SUITE 1680 SOUTH
INDIANAPOLIS, IN 46204
Holdings By Company
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| Surface Oncology, Inc. (SURF) Delisted | 10%+ Owner | 3,181,817 | $1.07 | $3.40M | $15.96M | 1 | 2018-04-23 |
| Rein Therapeutics, Inc. (ALRN) Delisted | 42,249 | $2.11 | $89.1K | $15.00M | 1 | 2017-07-07 | |
| PTGX | 10%+ Owner | 2,099,482 | $140.32 | $294.60M | $28.00M | 1 | 2016-08-16 |
| Spyre Therapeutics, Inc. (AGLE) Delisted | 10%+ Owner | 82,742 | $12.01 | $993.7K | $0 | 1 | 2016-04-14 |
| CHRS | 3,042,019 | $1.01 | $3.07M | $4.45M | 1 | 2014-11-12 | |
| Receptos, Inc. (RCPT) Delisted | 10%+ Owner | 1,938,353 | — | — | $2.00M | 1 | 2013-05-14 |
Recent Filings
6 filings| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2018-04-23 | Surface Oncology, Inc. (SURF) Delisted | Mixed | +13,791,268 | $15.96M | EDGAR |
| 2017-07-07 | Rein Therapeutics, Inc. (ALRN) Delisted | Mixed | +4,379,948 | $15.00M | EDGAR |
| 2016-08-16 | PTGX | Mixed | +8,397,928 | $28.00M | EDGAR |
| 2016-04-14 | Spyre Therapeutics, Inc. (AGLE) Delisted | Conv (C) | +6,032,772 | $0 | EDGAR |
| 2014-11-12 | CHRS | Mixed | +6,084,038 | $4.45M | EDGAR |
| 2013-05-14 | Receptos, Inc. (RCPT) Delisted | Mixed | +1,966,925 | $13.24M | EDGAR |
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.